What's Going On With Incannex Stock?
What's Going On With Incannex Stock?
Incannex Healthcare Inc. (NASDAQ:IXHL) shares are trading higher Wednesday after the company announced its Psi-GAD1 trial met its primary endpoint.
Incannex Healthcare Inc.（纳斯达克股票代码：IXHL）周三股价走高，此前该公司宣布其PSI-GAD1试验已达到其主要终点。
The Details:
细节：
Incannex said that its Phase 2 Psi-GAD1 clinical trial of psilocybin in generalized anxiety disorder met its primary endpoint of demonstrating a large clinical effect in the psilocybin treatment group over the placebo group.
Incannex表示，其针对广泛性焦虑症的psi-GAD1的2期psi-GAD1临床试验达到了其主要终点，即在迷幻药治疗组中比安慰剂组具有较大的临床效果。
"We are thrilled with the results from our initial PsiGAD trial," said Incannex CEO Joel Latham. "This is the first time psilocybin has been investigated for treatment of generalized anxiety disorder, and the reduction in HAM-A scores we have observed are far greater than those reported from trials on established medicines for treatment of anxiety."
Incannex首席执行官乔尔·莱瑟姆说：“我们对最初的PSIGad试验结果感到非常兴奋。”“这是首次研究psilocybin用于治疗广泛性焦虑症，我们观察到的HAM-A评分下降幅度远大于对成熟的焦虑治疗药物的试验中报告的降幅。”
Incannex has designed the follow-up Phase 2B clinical trial, PsiGAD2, with the assistance of Clerkenwell Health, and the trial will be conducted at multiple sites in the United States and United Kingdom.
Incannex在Clerkenwell Health的协助下设计了后续的2B期临床试验PSIgad2，该试验将在美国和英国的多个地点进行。
Related News: What's Going On With Carvana Stock?
相关新闻： Carvana 股票怎么了？
IXHL Price Action: According to Benzinga Pro, Incannex Healthcare shares are up 53% at $6.45 at the time of publication.
IXHL价格走势：根据Benzinga Pro的数据，Incannex Healthcare的股价在发布时上涨了53％，至6.45美元。
Image: Gordon Johnson from Pixabay
图片：来自 Pixabay 的戈登·约翰逊